Noven
products are sold in all
major international markets.
|
Over the past decade, Noven’s technological
advantages have attracted strategic partners who seek to offer leading-edge
transdermal
therapies, including:
| Novogyne
Pharmaceuticals |
In
the U.S., Noven has licensed its menopausal hormone therapy
patches to Novogyne Pharmaceuticals, a women’s health
products company that is a joint venture between Noven and
Novartis Pharmaceuticals Corporation. Vivelle-Dot®,
Novogyne’s
lead product, is the most dispensed transdermal estrogen
therapy in the U.S.
|
| Novartis
Pharma AG |
In
Europe, Noven has licensed its HT patches to Novartis Pharma
AG, a global leader in transdermal HT. Estradot®,
the international version of Vivelle-Dot®, is currently
available in European markets.
|
| Aventis
S.A. |
Noven has licensed its HT patches to Aventis
for marketing in Japan. |
Endo
Pharmaceuticals
|
Noven
and Endo have entered into a development collaboration for
innovative prescription patch products. |
| Shire
plc |
Noven has licensed global rights to Daytrana®,
its FDA-approved transdermal methylphenidate system, to Shire
plc, the market share leader in ADHD therapy. Noven has also
entered into a development collaboration with Shire for an
amphetamine patch. |
P&G
Pharmaceuticals,
Inc.
|
Noven
is developing new prescription patches for Procter & Gamble
Pharmaceuticals. These patches are follow-on products to
P&G’s
Intrinsa™ patch for the treatment
of HSDD. |
For
additional information, contact Noven
Business Development.
|
